Carcinoma, Non-Small-Cell-Lung Clinical Trial
Official title:
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
The purpose of this study is to evaluate the safety of I-PDT with Temoporfin for patients with Non-Resectable Non-Small-Cell Lung Cancer (NR-NSCLC). Several clinical studies suggested that photodynamic therapy (PDT) may be an effective treatment for patients with NR-NSCLC. PDT is a therapy where an external light source, such as laser, is used to activate a light-sensitive medicine to produce byproducts that can destroy cancer cells. In this study the investigators will use an experimental light sensitive medicine, Temoporfin, to perform interstitial PDT (I-PDT). In I-PDT, laser fibers are inserted into the tumor to activate the light-sensitive medicine.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Eighteen years of age and older, male or female, of all races and ethnicities. - Histologically confirmed non-small-cell lung cancer (NSCLC). - Not a candidate for curative surgery. - Not a candidate for curative concurrent chemoradiation therapy. - Not a candidate or does not wish to receive curative radiation therapy. - Not a candidate or does not wish to receive radiofrequency or microwave thermal ablation. - Have an Eastern Cooperative Oncology Group (ECOG) performance status < 2. - The tumor is observable in CT with contrast. - The tumor is accessible for unrestricted illumination of interstitial photodynamic therapy (I-PDT). - Deemed likely to survive for at least 3 months. - Patient is able and willing to provide written informed consent to participate in the study. - If the subject is a female of childbearing potential, the subject is willing to take a pregnancy test and practice strict birth control (estrogen-containing oral contraceptives or an intrauterine device) throughout the study and for 3 months after Temoporfin administration. Women who have had a hysterectomy are exempt from these requirements. - Subject is willing to remain in a controlled light exposure environment for a time period of at least 15 days. - History of laboratory tests that meet the following criteria - Hematocrit >= 33%, hemoglobin >= 11 g/dl - Platelet count > 70,000 per microliter - White blood count > 3,000 per microliter or ANC > 1500 per microliter - Creatinine: 0.8 to 1.4 mg/dL - Serum chloride: 101 to 111 mmol/L - Serum potassium: 3.7 to 5.2 mEq/L - Serum sodium: 136 to 144 mEq/L - Liver function test: albumin, bilirubin (direct/conjugated), ALT (alanine transaminase), AST (aspartate transaminade), GGT (gamma glutamyl transferase), ALP (alkaline phosphatase) within normal limits - BUN: 7 to 20 mg/dL Exclusion Criteria: - The tumor invades a major blood vessel. - The tumor is not clearly shown on the CT image. - The tumor size is larger than 5 cm when measured in a contrasted CT image according to RECIST v1.1. - The location and extension of the tumor precludes an effective I-PDT. - Patient with porphyria or other diseases exacerbated by light. - Patient with hypersensitivity to Temoporfin or to any of its excipients. - Patient with known allergies/hypersensitivity to porphyrins. - Patient with a planned surgical procedure within the next 30 days. - Patient with a coexisting ophthalmic disease likely to require slit-lamp examination within the next 30 days. - Patient with existing therapy with a photosensitizing agent (Temoporfin, porphyrin or derivatives of porphyrin). - Patient has received prior PDT to the proposed treatment site within the prior 3 months. - Patient with known sensitivity to the CT contrast agent (Omnipaque), which would preclude the use of the CT contrast agent. - History of poor renal function as demonstrated by serum creatinine and estimated glomerular filtration rate (eGFR) < 40 mL/min/1.73m2, which would preclude the using of the CT contrast agent. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
Lead Sponsor | Collaborator |
---|---|
University of Arkansas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of serious adverse events | The specific aim of this pilot study is to evaluate the safety of CT-guided I-PDT with Temoporfin on patients with NR-NSCLC. Patient safety will be the primary endpoint. The safety of the intervention will be assessed at 14 and 30 days post-therapy. The primary outcome will be occurrence of Serious Adverse Events (SAE). | 14 and 30 days post-therapy | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02562027 -
SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer
|
N/A | |
Withdrawn |
NCT02419170 -
Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)
|
Phase 0 | |
Active, not recruiting |
NCT00122239 -
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
|
N/A | |
Terminated |
NCT02431169 -
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
|